Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,673 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201).
Song Y, Zhou K, Jin C, Qian Z, Hou M, Fan L, Li F, Ding K, Zhou H, Li X, Chen B, Sun X, Song X, Jiang M, Zhang Q, Liu L, Yu G, Hu Y, Zhao Z, Liu L, Xue H, Luo J, He B, Jin X, Zhao M, Li B, Xia Y, Zhu J. Song Y, et al. Among authors: qian z. Front Oncol. 2022 Jul 7;12:925236. doi: 10.3389/fonc.2022.925236. eCollection 2022. Front Oncol. 2022. PMID: 35875118 Free PMC article.
Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma.
Wang H, Feng J, Liu Y, Qian Z, Gao D, Ran X, Zhou H, Liu L, Wang B, Fang M, Zhou H, Huang Z, Tao S, Chen Z, Su L, Su H, Yang Y, Xie X, Wu H, Sun P, Hu G, Liang A, Li Z. Wang H, et al. Among authors: qian z. Signal Transduct Target Ther. 2024 Apr 17;9(1):99. doi: 10.1038/s41392-024-01798-0. Signal Transduct Target Ther. 2024. PMID: 38627366 Free PMC article. Clinical Trial.
Time to lymphoma treatment within 24 months in 'watch and wait' follicular lymphoma is associated with inferior outcomes: A multicentre analysis.
Liu J, Gao F, Zhang T, Wang J, Li Z, Liu L, Zhou H, Zhang X, Sun X, Zhang W, Xu B, Su L, Wen S, Tao R, Bai O, Zou L, Li L, Qiu L, Qian Z, Zhou S, Song Y, Zhang Q, Wang X, Zhang H. Liu J, et al. Among authors: qian z. Br J Haematol. 2024 Nov;205(5):1815-1824. doi: 10.1111/bjh.19770. Epub 2024 Sep 26. Br J Haematol. 2024. PMID: 39327747
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial.
Li Z, Jiang W, Zhou H, Cen H, Zhang M, Lv F, Zhang Q, Sun X, Liu L, Huang Y, Yang H, Gao S, He C, Yang W, Li W, Yu D, Yang Y, Cheng Y, Qian Z, Xiang Y, Guo Q, Xu B, Song Y, Zhang L, Lin L, Shen J, Yan F, Liu H, Zhang D, Wang J, Zhou M, Zhu X, Zhang W, Zhao W, Feng R, Zhang X, Jin J, Zhong M, Zhang M, Wang J, Jing H, Wang Z, Zhao H, Zhu J. Li Z, et al. Among authors: qian z. J Immunother Cancer. 2024 Oct 24;12(10):e008895. doi: 10.1136/jitc-2024-008895. J Immunother Cancer. 2024. PMID: 39455094 Free PMC article. Clinical Trial.
Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study.
Zhao P, Zhao S, Huang C, Li Y, Wang J, Xu J, Li L, Qian Z, Li W, Zhou S, Qiu L, Liu X, Chen Y, Jiang Y, Zheng Y, Chen D, Zhou H, Gao Y, Zhang Q, Zhang H. Zhao P, et al. Among authors: qian z. Hematol Oncol. 2025 Jan;43(1):e70017. doi: 10.1002/hon.70017. Hematol Oncol. 2025. PMID: 39641321
4,673 results